Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

C Renner, I Stehle, FT Lee, C Hall, B Catimel… - Cancer Immunology …, 2001 - Springer
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …
被引用次数：14 相关文章

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.

C Renner, I Stehle, FT Lee, C Hall… - Cancer Immunology …, 2001 - europepmc.org
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

C Renner, I Stehle, FT Lee, C Hall… - Cancer …, 2001 - pubmed.ncbi.nlm.nih.gov
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.

C Renner, I Stehle, FT Lee, C Hall… - Cancer Immunology …, 2001 - search.ebscohost.com
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

C Renner, I Stehle, FT Lee, C Hall… - Cancer Immunology …, 2001 - research.monash.edu
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …
[PDF] academia.edu

[PDF][PDF] Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

C Renner, I Stehle, FT Lee, C Hall… - Cancer Immunol …, 2001 - academia.edu
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

C Renner, I Stehle, FT Lee, C Hall, B Catimel… - Cancer Immunology …, 2001 - infona.pl
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkins lymphoma and Hodgkins lymphoma …

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

C Renner, I Stehle, FT Lee, C Hall… - Cancer Immunology …, 2001 - ncbi.nlm.nih.gov
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …

[引用][C] Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

C RENNER, I STEHLE, AM SCOTT… - Cancer immunology …, 2001 - pascal-francis.inist.fr
Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

C Renner, I Stehle, FT Lee, C Hall, B Catimel… - Cancer Immunology …, 2001 - elibrary.ru
Bispecific antibodies are currently being used in clinical trials in increasing numbers in the
areas of breast cancer, prostate cancer, non-Hodgkin's lymphoma and Hodgkin's lymphoma …